Matthieu Blons

h-index2
2papers

2 Papers

IVAug 29, 2025
Robust Pan-Cancer Mitotic Figure Detection with YOLOv12

Raphaël Bourgade, Guillaume Balezo, Hana Feki et al.

Mitotic figures represent a key histoprognostic feature in tumor pathology, providing crucial insights into tumor aggressiveness and proliferation. However, their identification remains challenging, subject to significant inter-observer variability, even among experienced pathologists. To address this issue, the MItosis DOmain Generalization (MIDOG) 2025 challenge marks the third edition of an international competition aiming to develop robust mitosis detection algorithms. In this paper, we present a mitotic figure detection approach based on the state-of-the-art YOLOv12 object detection architecture. Our method achieved an F1-score of 0.801 on the preliminary test set (hotspots only) and ranked second on the final test leaderboard with an F1-score of 0.7216 across complex and heterogeneous whole-slide regions, without relying on external data.

IVAug 28, 2025
Efficient Fine-Tuning of DINOv3 Pretrained on Natural Images for Atypical Mitotic Figure Classification (MIDOG 2025 Task 2 Winner)

Guillaume Balezo, Hana Feki, Raphaël Bourgade et al.

Atypical mitotic figures (AMFs) represent abnormal cell division associated with poor prognosis. Yet their detection remains difficult due to low prevalence, subtle morphology, and inter-observer variability. The MIDOG 2025 challenge introduces a benchmark for AMF classification across multiple domains. In this work, we fine-tuned the recently published DINOv3-H+ vision transformer, pretrained on natural images, using low-rank adaptation (LoRA), training only ~1.3M parameters in combination with extensive augmentation and a domain-weighted Focal Loss to handle domain heterogeneity. Despite the domain gap, our fine-tuned DINOv3 transfers effectively to histopathology, reaching first place on the final test set. These results highlight the advantages of DINOv3 pretraining and underline the efficiency and robustness of our fine-tuning strategy, yielding state-of-the-art results for the atypical mitosis classification challenge in MIDOG 2025.